Mutations in the BRCA1 and BRCA2 genes confer a high lifetime risk of breast and ovarian
cancer. The risk varies from individual to individual, and it appears that the risk has …

Background: BRCA1 and BRCA2 mutations in general populations and in various types of
cancers have not been well characterized. We investigated the presence of these mutations …

Breast cancer is a genetic disease. The cancer phenotype is defined by a complex interplay
between oncogenes, tumor-suppressor genes and epigenetic factors. Only 5–10% of all …

A positive family history of breast cancer, reflecting genetic susceptibility, is one of the
strongest risk factors for the disease. A number of breast cancer susceptibility genes have …

Approximately 5–10% of breast carcinomas and 10% of ovarian carcinomas are ascribable
to a genetic susceptibility. Of these, about 40% are related to genetic mutations in the genes …

BRCA2 (BReast CAncer susceptibility gene 2) germline mutation carriers are at increased
risk for breast and ovarian cancers. Mutations occurring in the ovarian cancer cluster region …

We conducted an exploratory, qualitative study investigating experiences of women who
had developed breast cancer under the age of 40 and who were identified as BRCA1 or …

OBJECTIVE.: Hormone replacement therapy (HRT) is commonly prescribed to alleviate the
climacteric symptoms of menopause. Recent findings from the Women's Health Initiative has …

Kenneth Offit the proportion is four times higher), and the associations of cancer risks
according to position of the mutation within the BRCA2 gene are consistent with previous …

Background: Mutations in the BRCA1 (MIM 113705) gene are found in many families with
multiple cases of breast and ovarian cancer, and women with a BRCA1 mutation are at …